BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor modelsUlrike Rauh, Todd R. Golub, Stefan Kaulfuß et al.|Nature Cancer|2024Cited by 28
Abstract LB_A01: Rapidly cleared MCL1 inhibitor TTX-810 showing robust efficacy in preclinical tumor models with no effects on cardiomyocytes in vitro and in vivoUlrike Rauh, Todd R. Golub, Virendar K. Kaushik et al.|Molecular Cancer Therapeutics|2023Cited by 1